During this panel discussion we will focus our attention on how emerging and small manufacturers can effectively communicate the value of their respective new treatments with PBM’s. We will explore what PBM’s find valuable working with emerging and small manufacturers and the areas of opportunity emerging and small manufacturers have to work with PBM’s.

UAN: 0841-0000-22-005-L04-P

The COVID-19 pandemic has been a significant disruptor to patient care across the health care system.  Patient visits with physicians declined, prescription drug prescribing and utilization were significantly impacted, and a new “normal” has emerged.  Doug Long will break down the data to highlight the pandemic’s impact on Specialty pharmaceutical care and discuss what the new normal may look like.

By attending this session, you should be able to:

• recognize where the US Specialty Pharmaceutical market growth has been and near-term forecast for growth;
• identify the fastest growing Specialty classes and products and the slowest growing;
• understand new and future launches; and
• identify which factors will affect future growth.

UAN: 0841-0000-22-007-L04-P

As health care continues to evolve, coupled with an unprecedented demand for services and transformative delivery models, physicians, pharmacists, and healthcare professionals are re(engineering) the care team approach and ecosystem. This session will explore the growing trend for integrated team-based care models to drive coordinated treatment planning, whole patient care management, and how this may reshape the interactions with pharmaceutical manufacturers.

By attending this session, you should be able to:

• Recognize the different provider payment risk models and how this can change the “payor” landscape;
• Explore an integrated care model ecosystem aimed at reshaping physician and pharmacist engagement to achieve better patient outcomes and value; and
• Identify emerging trends that pharmaceutical companies, health plans, and PBMs can impact to reshape health care or prescription transactions.

UAN: 0841-0000-22-006-L04-P

The US biosimilars market has largely been focused on medical benefit therapies, but the pharmacy benefit biosimilar market will see rapid growth in the coming years .  Emily and Jon will discuss  past, present and future adoption, compare the US market evolution  with the EU experience, and discuss key considerations for the future.

By attending this session, you should be able to:

• Recognize past and current US biosimilar adoption rates;
• Describe the pipeline of future biosimilar introductions ; and
• Understand the ways US payers may optimize biosimilar education and uptake.

UAN: 0841-0000-22-009-L04-P

Over the past five years, there have been an increasing number of novel drugs that have been approved by the FDA with 59 new drugs being approved in 2021.  Linda Isham will discuss how PBMs are tracking the clinical pipeline and the information that is necessary to support P&T Committee decision making.

By attending this session, you should be able to:

• Understand trends on novel drug approvals and disease states;
• Discuss practices used by PBMs to monitor the drug development pipeline; and
• Identify opportunities to enhance components of the drug development pipeline to support P&T decisions.

UAN: 0841-0000-22-008-L04-P

A substantial portion of employee’s in the commercial market are on a self funded platform for their employer sponsored health plan. High cost Rx / therapies are compromising the integrity of the employee’s claim fund, forcing employer’s & carrier’s to shift liability. Matt Paul will highlight the basics of a self funded plan and the thought process around why this is occurring.

By attending this session, you should be able to:

• Understand why groups choose to self fund their employee medical plan;
• List what types of groups self fund;
• Describe the size of the commercial market on a self funded platform;
• Identify the reason for purchasing stop loss insurance;
• List the reason for lasering; and
• Identify why groups are carving Specialty Rx / infusion therapies out of the plan.